Skip to content

Study · Observational study · n = 200 · 2024

4 results

Liraglutide does not increase heart rate of diabetic patients during acute myocardial infarction.

Li Q, Wu C, Sun S, Yang L, Li Y, Niu Y, Zhang L, Li W, Yu Y

Journal of diabetes3 Jan 2024Cited by 2 (Europe PMC)

PMID38173120 (opens in a new tab)PMCIDPMC11212302 (opens in a new tab)DOI10.1111/1753-0407.13517 (opens in a new tab)PepBankPUB-38173120
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

BackgroundGlucagon-like peptide 1 receptor agonists have been shown to reduce all-cause and cardiovascular mortality in patients with Type 2 diabetes mellitus (T2DM). The probable increase in heart rate hinders its early usage in acute myocardial infarction patients. In our study, we aimed to find out whether the use of liraglutide in patients with acute myocardial infarction as early as at the time of hospitalization would increase the heart rate.MethodsThis was an observational retrospective study. From December 2020 to August 2021, 200 patients with acute myocardial infarction were included in our study and divided into three groups: T2DM + liraglutide group (n = 46), T2DM + non-liraglutide group (n = 42), and non-T2DM group (n = 112). The primary outcomes were the differences in heart rate. Secondary outcomes were differences in systolic and diastolic blood pressure.ResultsThere were no significant differences in heart rate among the three groups at admission, the day before the first shot of liraglutide, and before discharge. There was also no significant difference in heart rate between diabetic patients with acute myocardial infarction and those on liraglutide during the hospital stay. And there were no differences of beta-blocker dosages among the three groups. Liraglutide did not affect the blood pressure during acute myocardial infarction.ConclusionsLiraglutide did not increase the heart rate in diabetic patients during acute myocardial infarction and did not lead to an increase in the dose of beta-blockers in the patients. It also had no effect on blood pressure and showed better efficacy in lowering glucose levels without additional hypoglycemic events.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studySafety outcome

    In patients with acute myocardial infarction, heart rate did not differ significantly among the liraglutide, diabetic non-liraglutide and non-diabetic groups at admission, the day before the first liraglutide shot, or before discharge.

    In plain wordsIn patients with a heart attack, heart rate did not differ between the liraglutide, diabetic non-liraglutide and non-diabetic groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeHeart rate at admission, before first liraglutide shot and before discharge
    Study

    n = 200

    Comparator
    T2DM non-liraglutide group and non-T2DM group
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were no significant differences in heart rate among the three groups at admission, the day before the first shot of liraglutide, and before discharge.
    2 context sentences
    Summary · context
    This was an observational retrospective study.
    Summary · context
    From December 2020 to August 2021, 200 patients with acute myocardial infarction were included in our study and divided into three groups: T2DM + liraglutide group (n = 46), T2DM + non-liraglutide group (n = 42), and non-T2DM group (n = 112).
  2. 02HumanObservational studySafety outcome

    In diabetic patients with acute myocardial infarction, heart rate during the hospital stay did not differ significantly between those on liraglutide and those not on it.

    In plain wordsIn diabetic patients with a heart attack, heart rate in hospital was not different for those given liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeHeart rate during hospital stay, liraglutide versus diabetic controls
    Study

    n: not reported in source

    Comparator
    T2DM non-liraglutide group
    Analysis
    Primary
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was also no significant difference in heart rate between diabetic patients with acute myocardial infarction and those on liraglutide during the hospital stay.
    2 context sentences
    Summary · context
    This was an observational retrospective study.
    Summary · context
    From December 2020 to August 2021, 200 patients with acute myocardial infarction were included in our study and divided into three groups: T2DM + liraglutide group (n = 46), T2DM + non-liraglutide group (n = 42), and non-T2DM group (n = 112).
  3. 03HumanObservational studySafety outcome

    In this retrospective study of patients with acute myocardial infarction, liraglutide use was not associated with a change in blood pressure.

    In plain wordsIn a retrospective study of heart attack patients, liraglutide use was not linked to a change in blood pressure.

    Peptide
    Liraglutide
    Outcome
    No significant changeBlood pressure
    Study

    n: not reported in source

    Comparator
    T2DM non-liraglutide group and non-T2DM group
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide did not affect the blood pressure during acute myocardial infarction.
    2 context sentences
    Summary · context
    This was an observational retrospective study.
    Summary · context
    From December 2020 to August 2021, 200 patients with acute myocardial infarction were included in our study and divided into three groups: T2DM + liraglutide group (n = 46), T2DM + non-liraglutide group (n = 42), and non-T2DM group (n = 112).
  4. 04HumanObservational studySafety outcome

    In patients with acute myocardial infarction, beta-blocker dosages did not differ among the liraglutide, diabetic non-liraglutide and non-diabetic groups.

    In plain wordsIn patients with a heart attack, beta-blocker doses were not different between the three groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeBeta-blocker dosage
    Study

    n = 200

    Comparator
    T2DM non-liraglutide group and non-T2DM group
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    And there were no differences of beta-blocker dosages among the three groups.
    2 context sentences
    Summary · context
    This was an observational retrospective study.
    Summary · context
    From December 2020 to August 2021, 200 patients with acute myocardial infarction were included in our study and divided into three groups: T2DM + liraglutide group (n = 46), T2DM + non-liraglutide group (n = 42), and non-T2DM group (n = 112).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.